CivaTech Oncology walks to end Pancreatic Cancer at PurpleStride events in Philadelphia, Atlanta

CivaTech Oncology raises funds, awareness for world’s toughest cancer at PurpleStride
October 30, 2017

 

RESEARCH TRIANGLE PARK, NC — CivaTech Oncology® is a sponsor and will participate in PurpleStride events this Saturday, November 4, in Philadelphia, PA and next Saturday, November 11, in Atlanta, GA. CivaTech Oncology supports Pancreatic Cancer Action Network’s (PanCAN) urgent mission to save lives and double survival by 2020.  CivaTech, a medical device company dedicated to localized radiation therapy, is conducting two clinical trials funded by NIH/NCI to evaluate the efficacy of CivaSheet® to reduce the local recurrence rate of pancreatic cancer.

“Compared to current standards of treatment, CivaSheet can safely deliver a significantly increased dose of radiation directly to the tumor site, that may reduce the chances a patient’s pancreatic cancer will return.” says CivaTech CEO and Founder Suzanne Babcock. “Never before have we been able to deliver a targeted, localized therapeutic radiation dose for pancreatic cancer.”

Pancreatic cancer is the world’s toughest cancer with a five-year survival of just 9 percent. Following surgery, over 50% of patients may experience local recurrence, or return of the disease. Treatment with CivaSheet aims to reduce the local recurrence rate and improve a patient’s odds of remaining cancer free after surgery.

Each person who dies from pancreatic cancer – an estimated 43,000 Americans this year – is a mother, daughter, father, son, sister, brother, colleague or friend. PanCAN fights for every one of them.

To learn more about the Pancreatic Cancer Action Network and how you can make a difference, visit pancan.org.

About the Pancreatic Cancer Action Network (PanCAN)
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double survival by 2020.

About CivaTech Oncology Inc.
CivaTech Oncology is a medical device company dedicated to localized “radiation therapy without the beam.” The implantable CivaSheet features a polymer encapsulated Pd-103 source with embedded gold shielding to deliver a therapeutic dose of radiation on one side of the device, and shield healthy tissues on the other side. CivaSheet® is the only LDR brachytherapy device with a customizable dose for each patient and unique, directional dose delivery, designed to maximize radiation benefits and prevent unwanted side effects.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *